[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio2f1af83e":3},{"user":4,"document":8,"mainDocument":44,"columnUrl":46,"subscription":47,"footer":59,"text":94},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":40,"videoId":6,"liveVideoUrl":6,"duration":41,"price":41,"priceText":42,"priceBadgeText":42,"priceBadgeClass":43,"freeForMinGroupLevel":41,"redirectUrl":6,"readyToStream":5},"dcio2f1af83e","全球治疗癌症的上市公司列表","\u002Fdoc\u002Fdcio2f1af83e","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>治疗癌症（Oncology \u002F 肿瘤治疗）的上市公司非常多，大致可以分成三类：\u003C\u002Fp>\u003Cp>1 大型制药巨头（稳定、现金流强）\u003Cbr>2 专注肿瘤的Biotech公司（成长型）\u003Cbr>3 临床阶段的小型Biotech（高风险高回报）\u003C\u002Fp>\u003Cp>下面美股大数据 StockWe.com 整理一个美股\u002F全球癌症治疗公司地图，很多机构投资者就是按这个框架看的。\u003C\u002Fp>\u003Cp>一、全球癌症药物巨头（收入最大）\u003C\u002Fp>\u003Cp>这些公司拥有成熟药物 + 巨大销售额。\u003C\u002Fp>\u003Cp>1 Merck（MRK）\u003C\u002Fp>\u003Cp>代表药物：\u003C\u002Fp>\u003Cp>Keytruda（全球最赚钱抗癌药）\u003Cbr>Keytruda\u003Cbr>2024年销售\u003C\u002Fp>\u003Cp>约295亿美元\u003C\u002Fp>\u003Cp>是全球第一抗癌药。\u003C\u002Fp>\u003Cp>主要治疗：\u003C\u002Fp>\u003Cp>肺癌\u003Cbr>黑色素瘤\u003Cbr>肾癌\u003Cbr>胃癌\u003Cbr>\u003Cbr>2 Bristol-Myers Squibb（BMY）\u003C\u002Fp>\u003Cp>核心抗癌药：\u003C\u002Fp>\u003Cp>Opdivo\u003Cbr>Revlimid\u003Cbr>Breyanzi\u003Cbr>Abecma\u003Cbr>2024年\u003C\u002Fp>\u003Cp>肿瘤收入约248亿美元。\u003C\u002Fp>\u003Cp>3 AstraZeneca（AZN）\u003C\u002Fp>\u003Cp>重点药：\u003C\u002Fp>\u003Cp>Tagrisso（肺癌）\u003Cbr>Enhertu（ADC药物）\u003Cbr>Lynparza（PARP抑制剂）\u003Cbr>2024年肿瘤销售\u003C\u002Fp>\u003Cp>223亿美元。\u003C\u002Fp>\u003Cp>4 Roche（ROG \u002F OTC: RHHBY）\u003C\u002Fp>\u003Cp>癌症领域老大之一\u003C\u002Fp>\u003Cp>经典药物：\u003C\u002Fp>\u003Cp>Herceptin\u003Cbr>Avastin\u003Cbr>Rituxan\u003Cbr>属于精准医疗 + 诊断+药物结合模式\u003C\u002Fp>\u003Cp>5 Johnson & Johnson（JNJ）\u003C\u002Fp>\u003Cp>代表药物：\u003C\u002Fp>\u003Cp>Darzalex（多发性骨髓瘤）\u003Cbr>Carvykti（CAR-T）\u003Cbr>2025年\u003C\u002Fp>\u003Cp>癌症药销售\u003C\u002Fp>\u003Cp>超过250亿美元。\u003C\u002Fp>\u003Cp>二、肿瘤Biotech龙头（成长型）\u003C\u002Fp>\u003Cp>这些公司更偏创新药公司。\u003C\u002Fp>\u003Cp>1 Amgen（AMGN）\u003C\u002Fp>\u003Cp>重点：\u003C\u002Fp>\u003Cp>BiTE免疫疗法\u003Cbr>KRAS抑制剂\u003Cbr>\u003Cbr>2 Gilead（GILD）\u003C\u002Fp>\u003Cp>收购 Kite Pharma 后\u003C\u002Fp>\u003Cp>重点：\u003C\u002Fp>\u003Cp>CAR-T疗法\u003C\u002Fp>\u003Cp>代表药：\u003C\u002Fp>\u003Cp>Yescarta\u003Cbr>Tecartus\u003Cbr>\u003Cbr>3 Incyte（INCY）\u003C\u002Fp>\u003Cp>重点领域：\u003C\u002Fp>\u003Cp>血液癌症\u003Cbr>JAK抑制剂\u003Cbr>主要药：\u003C\u002Fp>\u003Cp>Jakafi\u003Cbr>公司专注于肿瘤和免疫疾病药物开发。\u003C\u002Fp>\u003Cp>4 AbbVie（ABBV）\u003C\u002Fp>\u003Cp>代表抗癌药：\u003C\u002Fp>\u003Cp>Imbruvica\u003Cbr>Venclexta\u003Cbr>用于\u003C\u002Fp>\u003Cp>白血病\u003Cbr>淋巴瘤。\u003Cbr>\u003Cbr>三、专注癌症的Biotech公司\u003C\u002Fp>\u003Cp>这些公司几乎只做肿瘤药。\u003C\u002Fp>\u003Cp>1 BeiGene \u002F BeOne Medicines（BGNE）\u003C\u002Fp>\u003Cp>中国+美国双总部\u003C\u002Fp>\u003Cp>主要药：\u003C\u002Fp>\u003Cp>Tislelizumab（PD-1）\u003Cbr>Zanubrutinib（BTK抑制剂）\u003Cbr>属于全球化肿瘤药公司。\u003C\u002Fp>\u003Cp>2 BioNTech（BNTX）\u003C\u002Fp>\u003Cp>除了疫苗\u003C\u002Fp>\u003Cp>核心未来：\u003C\u002Fp>\u003Cp>癌症mRNA疫苗\u003C\u002Fp>\u003Cp>2025年\u003C\u002Fp>\u003Cp>和BMS合作开发抗癌抗体。\u003C\u002Fp>\u003Cp>3 Verastem Oncology（VSTM）\u003C\u002Fp>\u003Cp>专注：\u003C\u002Fp>\u003Cp>靶向肿瘤药物开发。\u003Cbr>\u003Cbr>4 Oncolytics Biotech（ONCY）\u003C\u002Fp>\u003Cp>专注：\u003C\u002Fp>\u003Cp>溶瘤病毒治疗癌症\u003Cbr>\u003Cbr>四、最火的癌症技术路线（现在资本最关注）\u003C\u002Fp>\u003Cp>当前癌症药物主要有5条技术路线：\u003C\u002Fp>\u003Cp>① 免疫疗法（Immunotherapy）\u003C\u002Fp>\u003Cp>代表公司\u003C\u002Fp>\u003Cp>MRK\u003Cbr>BMY\u003Cbr>AZN\u003Cbr>药物：\u003C\u002Fp>\u003Cp>PD-1\u003Cbr>PD-L1\u003Cbr>\u003Cbr>② CAR-T细胞疗法\u003C\u002Fp>\u003Cp>代表公司\u003C\u002Fp>\u003Cp>GILD\u003Cbr>JNJ\u003Cbr>BMY\u003Cbr>\u003Cbr>③ ADC（抗体偶联药）\u003C\u002Fp>\u003Cp>最近最火\u003C\u002Fp>\u003Cp>代表公司\u003C\u002Fp>\u003Cp>AZN\u003Cbr>Daiichi Sankyo\u003Cbr>Seagen（被PFE收购）\u003Cbr>\u003Cbr>④ mRNA癌症疫苗\u003C\u002Fp>\u003Cp>代表公司\u003C\u002Fp>\u003Cp>BNTX\u003Cbr>Moderna\u003Cbr>\u003Cbr>⑤ 小分子靶向药\u003C\u002Fp>\u003Cp>代表公司\u003C\u002Fp>\u003Cp>Novartis\u003Cbr>Amgen\u003Cbr>AbbVie\u003Cbr>\u003Cbr>五、如果你是做投资（最值得关注的肿瘤股）\u003C\u002Fp>\u003Cp>美股投资网给你一个机构最常看的名单：\u003C\u002Fp>\u003Cp>超级巨头（最稳）\u003C\u002Fp>\u003Cp>MRK\u003Cbr>AZN\u003Cbr>BMY\u003Cbr>JNJ\u003Cbr>中型成长\u003C\u002Fp>\u003Cp>AMGN\u003Cbr>GILD\u003Cbr>INCY\u003Cbr>BGNE\u003Cbr>高风险Biotech\u003C\u002Fp>\u003Cp>SLS\u003Cbr>ONCY\u003Cbr>ACLX\u003Cbr>VSTM\u003Cbr>一个重要行业趋势\u003C\u002Fp>\u003Cp>癌症市场规模预计：\u003C\u002Fp>\u003Cp>2026 = 2790亿美元\u003C\u002Fp>\u003Cp>到2035年\u003C\u002Fp>\u003Cp>约7500亿美元。\u003C\u002Fp>\u003Cp>所以肿瘤是医药里最大赛道之一。\u003C\u002Fp>","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202603-stk\u002FUploader212a21mx12k_2026_03_11_14_30_39.png","2026-03-11T21:20:11.683","2026.03.11","2026\u002F03\u002F11",45962,[22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"MRK","BMY","AZN","RHHBY","JNJ","AMGN","GILD","INCY","ABBV","BGNE","BNTX","VSTM","ONCY","MRNA","NVS","PFE","SLS","ACLX","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":45,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":40,"videoId":6,"liveVideoUrl":6,"duration":41,"price":41,"priceText":42,"priceBadgeText":42,"priceBadgeClass":43,"freeForMinGroupLevel":41,"redirectUrl":6,"readyToStream":5},[22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":48,"services":49,"recentDocuments":58},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[50,54],{"productId":51,"serviceName":52,"priceText":53},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":55,"serviceName":56,"priceText":57},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":60,"images":85,"summaryHtml":90,"aboutTitle":91,"aboutHtml":92,"copyrightHtml":93},[61,64,67,70,73,76,79,82],{"label":62,"url":63},"深度报告","\u002Fcol\u002FdepthReport",{"label":65,"url":66},"VIP会员","\u002Fplan",{"label":68,"url":69},"期权推荐","\u002FOption",{"label":71,"url":72},"低价暴涨股","\u002FPenny",{"label":74,"url":75},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":77,"url":78},"美股课程","\u002Fcol\u002Fvideos",{"label":80,"url":81},"免责声明","\u002Fdisclaimer",{"label":83,"url":84},"联系我们","\u002FContactUs",[86,87,88,89],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 StockWe.com 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理千万级股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":95,"search":96,"searchPlaceholder":96,"hotContent":97,"draft":98,"noData":99,"searchNoData":100,"edit":101,"editVideo":102,"courseContent":103,"more":104,"buyNow":105,"subscribeNow":106,"encoding":107,"paidContent":108},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]